Below is a twelve month price history chart comparing the stock performance of DVAX, IMDZ, and NK: Below is a summary table of the …
NASDAQ
Dynavax Technologies Corporation (NASDAQ:DVAX) has been given an average recommendation of “Hold” by the seven research firms that are covering the stock. Four research analysts have rated the stock with a hold …
BNS1d
Dynavax Technologies Corporation
That means there’s plenty of reward left even after today’s gains, especially if Heplisav gets FDA-approval. Just remember: The biotech space is highly volatile, and that’s reflected in the DVAX stock price in 2016.
Gain
On September 2, DVAX fell over 32% after the FDA canceled the advisory committee meeting for November, saying it needed time to review and resolve several outstanding issues. On October 3, DVAX disclosed that it …
Corporation
Dynavax Technologies Corporation (NASDAQ:DVAX) VP Robert Janssen acquired 6,000 shares of the business’s stock in a transaction on Tuesday, January 24th. The shares were purchased at an average cost of $4.04 per …
Stock
Dynavax Technologies Corporation (NASDAQ:DVAX) stock is down over 11% today, based on the company’s announcement that the Food and Drug Administration (FDA) has extended its review process of Biologic …
NASDAQ
Dynavax Technologies is having an incredible day in the market today, and for good reason. Early this morning, the company announced that it has received anticipated requests from the US FDA for more information with …
Stock
Investors in shares of Dynavax Technologies Corporation (DVAX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Call which expires on Jan 20, 2017 for …
ZACKS2mon
The consensus analyst recommendation is 2.30 on Dynavax Technologies Corporation (NASDAQ:DVAX). Finally, RBC Capital Markets restated a "sector perform" rating and set a $16.00 target price on shares of Dynavax …